Skip to the stories
Wednesday, 18 November 2026
Saved

Next edition

7:04

Headlines

Medical Science

Ensysce Biosciences reports third quarter 2026 financial and clinical developments

Ensysce Biosciences completed a biopharma acquisition, advanced regulatory filings for its pain treatment pipeline, and ended the third quarter of 2026 with 29.7 million dollars in cash.

FTMQ Health, written by our newsroom1 view

Share

Ensysce Biosciences announced its third quarter 2026 financial results and operational milestones on November 12, 2026, according to reports from TradingView and scanx.trade. The clinical-stage biotechnology company completed its acquisition of Cy Biopharma, which adds the lead candidate CY200 to its drug development pipeline for complex regional pain syndrome. TradingView and scanx.trade both reported on the company's quarter-end updates. [1][4]

TradingView reported that Ensysce Biosciences submitted a Phase 2a clinical protocol for CY200 to the UK Medicines and Healthcare products Regulatory Agency. In addition, the company finished participant enrollment in the final stage of its PF614-MPAR-102 study. According to scanx.trade, the company's third quarter revenue increased by 342 percent, while its net loss widened to 0.13 dollars per share. [1][4]

TradingView reported that the San Diego, California-based company ended the third quarter of 2026 with 29.7 million dollars in cash and cash equivalents. Other biotechnology firms, including Armata Pharmaceuticals and Assembly Biosciences, also announced their third quarter 2026 financial results on the same day, according to StreetInsider and Yahoo Finance. [1][2][3]

Share

In short

  • Ensysce Biosciences completed its acquisition of Cy Biopharma, acquiring the CY200 pipeline asset for complex regional pain syndrome.
  • The company submitted a Phase 2a protocol for CY200 to the UK Medicines and Healthcare products Regulatory Agency.
  • Ensysce Biosciences completed participant enrollment in the final stage of the PF614-MPAR-102 study.
  • Ensysce Biosciences ended the third quarter of 2026 with 29.7 million dollars in cash and cash equivalents.

Sources

Every paragraph above points to the numbered items it rests on. Read the originals here.

  1. [1]Ensysce Biosciences Reports Third Quarter 2026 Financial Results and Business HighlightsTradingView, 5d ago (the report this story comes from)
  2. [2]Armata Pharmaceuticals Announces Financial Results for the Third Quarter 2026 and Provides Corporate UpdateStreetInsider, 5d ago
  3. [3]Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent UpdatesYahoo Finance, 5d ago
  4. [4]Ensysce Biosciences Q3 Results: Loss widens to $0.13, revenue jumps 342%scanx.trade, 5d ago

Background

  1. [5]List of largest biomedical companies by revenue on Wikipedia
  2. [6]Highlights (magazine) on Wikipedia
  3. [7]Experimental weight loss drug retatrutide reduces knee pain in trials FTMQ Health, 9d ago
  4. [8]BrightSpring Health Services raises 2026 outlook following third quarter earnings growth FTMQ Health, 10d ago

Our newsroom writes these reports with the help of software, from the 8 sources listed and nothing else, and checks them against those sources. Facts can still be wrong or move on; the originals are the record. Spotted a mistake? Write to daniel@monsterkong.com.

Earlier reports of ours on the same people and subjects.

More in Medical Science

Get the day in one email

Reports like this one, the top news of the last 24 hours, every morning. Free, one email a day; readers can comment under every report.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.

Comments

Loading

Join the conversation

Comments are open to readers of our daily email: the top news of the last 24 hours, every morning, free. Sign up and the comment box opens.

Already on the list? Enter the same address and we will send a sign-in link.

By signing up you agree to our terms and privacy policy. Unsubscribe any time.